Meningococcal infection

This Phase 3 trial tests a new vaccine designed to protect infants aged 3 to 5 months against four strains of meningococcal bacteria that cause meningitis and sepsis. About 880 healthy babies will receive either the experimental vaccine or a licensed comparator vaccine. Researche…

This Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis. About 1,040 healthy infants aged 6 to 11 months will receive either the experimental vaccine or a licensed comparator. Researchers will measure immune respon…

This study tests a new vaccine to protect young children (12-23 months old) against four types of meningococcal bacteria that can cause meningitis. About 1,040 toddlers will receive either the new vaccine or an existing one to see if the new vaccine is as safe and effective. The …

This study will monitor the safety of the MenQuadfi vaccine in 706 people aged 6 weeks to 55 years in South Korea. Researchers will track side effects like injection-site reactions and serious adverse events as the vaccine is used in real-world clinics. The goal is to confirm the…

This early-stage trial is testing a new vaccine called DX-104 to see if it is safe and triggers an immune response against group B meningococcal bacteria, which can cause meningitis. The study involves 30 healthy adults aged 18 to 50 who will receive either the new vaccine or an …

This early-stage trial is testing a new vaccine that combines protection against several serious childhood diseases: diphtheria, tetanus, whooping cough, meningitis, and Hib. The study involves 260 children aged 2 months to 6 years to check the vaccine's safety and immune respons…

This study tests a new vaccine called GNG-DE to see how well it protects against meningococcal infections (a cause of meningitis). About 240 people aged 3 to 55 will receive either the new vaccine or a reference vaccine. Researchers will measure immune responses and check for sid…

This study looks at whether a single booster dose of a meningitis B vaccine can protect young adults who got a different meningitis B vaccine at least 2.5 years ago. Researchers will measure immune responses in 125 healthy participants before and after the booster. The goal is to…

This study tests a new vaccine designed to protect against four types of meningococcal bacteria that can cause serious infections like meningitis and sepsis. About 1,100 healthy adults aged 19 to 55 will receive a single dose to see how well it triggers the immune system and if i…

This phase 3 trial is testing three different ways to give the meningococcal B vaccine to adults who have had their spleen removed. People without a spleen are at higher risk for serious infections. The study will compare how well each vaccine schedule triggers the immune system …

This registry study follows pregnant individuals aged 10 to 25 who received PENBRAYA, a vaccine against meningococcal disease, during pregnancy or within 30 days before their last period. The goal is to collect information on pregnancy outcomes and infant health during the first …

This study looks at whether sleep habits of 11-12 year olds affect their immune response to the meningococcal vaccine (MCV4). About 66 healthy teens will wear a sleep tracker and keep their normal sleep schedule for 5 weeks. Researchers will measure antibody levels after vaccinat…

This study looks at how well the MenFive (NmCV-5) meningitis vaccine still works more than five years after a single shot. Researchers will test the blood of 450 people in Mali and The Gambia who got the vaccine when they were 2 to 29 years old. The goal is to see if their immune…

This study looks at how a person's sex and gender might change their immune system's reaction to the meningitis B vaccine. Researchers will compare immune responses in transgender and cisgender adults aged 18 to 50. The goal is to better understand why men and women often respond…

This study monitors the safety of the MenQuadfi vaccine when given to pregnant women or within 30 days before their last period. Researchers will track side effects in mothers and health outcomes in babies, including birth defects and complications. About 50 women in the U.S. wil…